Potassium binder may unlock lifesaving heart drugs for seniors
NCT ID NCT06578078
First seen Mar 05, 2026 · Last updated Jun 22, 2026 · Updated 12 times
Summary
This study tests whether a potassium-lowering drug called sodium zirconium cyclosilicate (Lokelma) can help elderly patients with heart failure and chronic kidney disease safely take higher doses of RAASi medications, which are often limited by high potassium levels. The trial will enroll 94 people aged 70 and older, comparing those who get Lokelma plus standard RAASi therapy to those who get standard care alone. The main goal is to see if more patients can increase their RAASi dose by at least 25% over three months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Clínico Universitario de Valencia
RECRUITINGValencia, 46010, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitario Fundación Alcorcón
NOT_YET_RECRUITINGAlcorcón, Madrid, 28922, Spain
Contact Email: •••••@•••••
-
Hospital Universitario Nuestra Señora del Perpétuo Socorro
RECRUITINGAlbacete, 02006, Spain
Contact Email: •••••@•••••
-
Hospital Universitario Reina Sofía
NOT_YET_RECRUITINGCórdoba, 14004, Spain
Contact Email: •••••@•••••
-
Hospital Universitario Severo Ochoa
NOT_YET_RECRUITINGLeganés, Madrid, 28914, Spain
Contact Email: •••••@•••••
-
Hospital Universitario de Burgos
RECRUITINGBurgos, 09006, Spain
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sodium Zirconium Cyclosilicate (Lokelma)
What this could lead to
If successful, this could show a way to safely use life-saving heart and kidney medications in elderly patients who currently cannot due to high potassium levels.
What could go wrong
This is a small, early-phase trial (94 participants) focused on medication dosing, not hard outcomes like survival. The drug may not meaningfully improve long-term health.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.